HJLI - Hancock Jaffe Laboratories, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6895
+0.0275 (+4.15%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.6620
Open0.6680
Bid0.6895 x 1300
Ask0.8300 x 900
Day's Range0.6601 - 0.6920
52 Week Range0.3800 - 3.4500
Volume34,375
Avg. Volume88,729
Market Cap12.357M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • ACCESSWIRE

    Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present Updated VenoValve Data Next Week at the 32nd Annual Meeting of the American Venous Forum

    IRVINE, CA / ACCESSWIRE / February 26, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Wednesday, March 4, 2020, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Colombia, will present updated VenoValve data at the Thirty Second Annual Meeting of the American Venous Forum. The meeting is taking place March 3 to March 6 at the Omni Amelia Island Plantation Hotel at Amelia Island, Florida. Contemporaneously with Dr. Ulloa's presentation at the American Venous Forum meeting, HJLI will release select VenoValve data from the presentation, which will include updated reports from 8 patients that are 180 days post VenoValve surgery (including 1 Patient that is now 365 days post VenoValve surgery).

  • ACCESSWIRE

    Hancock Jaffe Reports Positive Results for 6 Month CoreoGraft Animal Feasibility Study

    IRVINE, CA / ACCESSWIRE / January 8, 2020 / Hancock Jaffe Laboratories, Inc. (HJLI), a developer of medical devices that restore cardiac and vascular health, today announced positive results from its six (6) month CoreoGraft animal feasibility study. At thirty (30), ninety (90), and one hundred and eighty (180) days post CoreoGraft bypass surgeries, all grafts were patent (open) when the implantations went smoothly and there were no technical errors. At the conclusion of the study, pathology examinations of the grafts and surrounding tissue showed no signs of thrombosis, infection, aneurysmal degeneration, changes in the lumen or other problems that are known to plague saphenous vein grafts ("SVGs").

  • ACCESSWIRE

    VenoValve Abstract Published in January 2020 Edition of Journal of Vascular Surgery

    IRVINE, CA / ACCESSWIRE / December 20, 2019 / Hancock Jaffe Laboratories, Inc. (HJLI)(HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that an abstract entitled Results of First-in-Human Implantation of a Prosthetic Venous Valve has been published in the January 2020 edition of the Journal of Vascular Surgery®. A presentation from the abstract will be delivered by Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Bogota, Colombia, at the 44th Annual Meeting of the Southern Association for Vascular Surgery ("SAVS"), which will take place January 8 to January 11 in Palm Beach, Florida.

  • Investors Who Bought Hancock Jaffe Laboratories (NASDAQ:HJLI) Shares A Year Ago Are Now Down 74%
    Simply Wall St.

    Investors Who Bought Hancock Jaffe Laboratories (NASDAQ:HJLI) Shares A Year Ago Are Now Down 74%

    Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply accept every...

  • ACCESSWIRE

    Hancock Jaffe Medical Team to Make Presentations at 46th Annual VEITH Vascular Symposium November 19 to November 23 in New York City

    IRVINE, CA / ACCESSWIRE / November 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's VenoValve study in Colombia, and Dr. Marc H. Glickman, HJLI's Senior Vice President and Chief Medical Officer, will be making presentations at the world renowned VEITH Vascular Symposium taking place November 19 to November 23 at the New York Hilton in New York City. Dr. Ulloa will be making two presentations on the VenoValve.

  • ACCESSWIRE

    Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient

    IRVINE, CA / ACCESSWIRE / November 15, 2019 / Hancock Jaffe Laboratories, Inc. (HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled and successfully implanted the 10th patient to complete the initial implantation phase of the first-in-man VenoValve study being conducted in Colombia. Hancock Jaffe's first-in-man study is the precursor to seeking permission from the U.S. Food and Drug Administration ("FDA") to conduct the VenoValve U.S. pivotal trial. In consultation with the FDA, HJLI agreed to conduct a first-in-man study of between five and ten patients that suffer from chronic venous insufficiency ("CVI").

  • ACCESSWIRE

    Principal Investigator Dr. Jorge Hernando Ulloa Presents 6 Month VenoValve Data at the 20th Congress of Asian Society for Vascular Surgery

    IRVINE, CA / ACCESSWIRE / October 24, 2019 / Hancock Jaffe Laboratories, Inc. (HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve study in Bogota, Colombia, presents new six (6) month VenoValve data at the 20th Congress of Asian Society for Vascular Surgery in Bali, Indonesia. Dr. Ulloa's presentation indicates that each of the first five (5) VenoValve patients continued to improve in all study end-points at six (6) months post VenoValve surgical implant, including average improvements of an additional ten (10) percentage points in reflux, two (2) percentage points in disease manifestations (VCSS scores), and thirteen (13) percentage points in pain (VAS scores), compared to levels at ninety (90) days post VenoValve surgeries.

  • ACCESSWIRE

    Principal Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Six Month Data at the 20th Congress of Asian Society for Vascular Surgery on October 25, 2019

    IRVINE, CA / ACCESSWIRE / October 22, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that ...

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference; Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • ACCESSWIRE

    Hancock Jaffe to Present at the Inaugural MicroCap Rodeo Investor Conference on October 16, 2019

    IRVINE, CA / ACCESSWIRE / October 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present ...

  • ACCESSWIRE

    Hancock Jaffe to Host Virtual Roadshow Webinar on Thursday, October 3, 2019 at 4:30 p.m. Eastern Time

    IRVINE, CA / ACCESSWIRE / September 26, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, will host a virtual ...

  • Hancock Jaffe Laboratories, Inc.'s (NASDAQ:HJLI) Single Biggest Risk For Investors
    Simply Wall St.

    Hancock Jaffe Laboratories, Inc.'s (NASDAQ:HJLI) Single Biggest Risk For Investors

    Trailing twelve-month data shows us that Hancock Jaffe Laboratories, Inc.'s (NASDAQ:HJLI) earnings loss has...

  • ACCESSWIRE

    The MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin TX.

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • ACCESSWIRE

    Hancock Jaffe Appoints Global Healthcare Executive Matthew Jenusaitis and Financial and Medical Reimbursement Expert Robert Gray to its Board of Directors

    IRVINE, CA / ACCESSWIRE / September 16, 2019 / Hancock Jaffe Laboratories, Inc. (HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has appointed global healthcare executive Mr. Matthew Jenusaitis and reimbursement and financial expert Mr. Robert Gray to its board of directors. Mr. Jenusaitis and Mr. Gray are filling two vacancies on the five member Hancock Jaffe board.

  • ACCESSWIRE

    Hancock Jaffe Medical Advisory Board Member Dr. Steven Elias Presents at International Union of Phlebology Conference in Krakow, Poland

    IRVINE, CA / ACCESSWIRE / August 29, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on August 25, 2019, Dr. Steven Elias, a member Hancock Jaffe's Medical Advisory Board, made a presentation which featured Hancock Jaffe's VenoValve, at the International Union of Phlebology Conference in Krakow, Poland. Dr. Elias's presentation was on artificial vein valves in the treatment of chronic venous disease and included a video from Dr. Jorge Ulloa, the principal investigator for Hancock Jaffe's first-in-man VenoValve study in Bogota, Colombia.

  • ACCESSWIRE

    Hancock Jaffe to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

    IRVINE, CA / ACCESSWIRE / August 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) (NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present ...

  • ACCESSWIRE

    Hancock Jaffe Successfully Completes Two Additional VenoValve Implantations for First-in-Man Study

    IRVINE, CA / ACCESSWIRE / August 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in two additional patients, as part of HJLI’s first-in-man Bogota study. Dr. Marc H. Glickman, Hancock Jaffe’s Senior Vice President and Chief Medical Officer, who was present at the surgeries in Bogota, Colombia stated, “Each time we implant VenoValves, the procedures get better and better. The first phase of the first-in-human Colombian study will be between five and ten patients who suffer from severe, chronic venous insufficiency (CVI) of the deep vein system, a condition that occurs when the valves in the veins of the venous system of the leg are injured or destroyed, causing blood to flow backwards (reflux) and pool in the lower extremities.

  • ACCESSWIRE

    Hancock Jaffe Reports Positive 90 Day Results for CoreoGraft Animal Feasibility Study

    IRVINE, CA / ACCESSWIRE / August 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. For the three (3) test subjects that were evaluated via angiogram ninety (90) days post CoreoGraft bypass surgery, the CoreoGrafts are functioning perfectly with no signs of thrombosis, aneurysmal degeneration, neointimal hyperplasia, changes in the lumen, or other problems that are known to plague saphenous vein grafts ("SVGs") and attempts by others to create small caliber (3 mm and 4 mm) grafts. Dr. Marc H. Glickman, Hancock Jaffe's Chief Medical Officer stated, “Having small caliber grafts that look this good at 90 days post-surgery is a significant milestone for Hancock Jaffe.

  • ACCESSWIRE

    Principle Investigator Dr. Jorge Hernando Ulloa Reports New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean

    IRVINE, CA / ACCESSWIRE / July 26, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, the Principle Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, reported new 90 day VenoValve data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean. Dr. Ulloa reported that for all four patients with working VenoValves, reflux has been reduced to normal levels seen in patients without Chronic Venous Insufficiency ("CVI"). Dr. Ulloa also reported that overall, reflux has been reduced an average of sixty-eight (68%) across all patients with the working VenoValves device, significantly more than the forty five percent (45%) reduction that was reported this past June, at which time patients were 60 days post-surgery.

  • ACCESSWIRE

    Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean On July 25, 2019

    IRVINE, CA / ACCESSWIRE / July 19, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, Principal Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, will present new 90 day VenoValve data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean. The conference is taking place July 25 to July 27 in the Dominican Republic. In conjunction with Dr. Ulloa's presentation, on July 25, 2019, at 11:00 am Eastern time, Dr. Marc H. Glickman, Hancock Jaffe's Senior Vice President and Chief Medical Officer, and Mr. Robert A. Berman, Hancock Jaffe's Chief Executive Officer, will host a webcast and conference call to present select slides from Dr. Ulloa's presentation and to answer any shareholder questions about the VenoValve.

  • ACCESSWIRE

    Hancock Jaffe Reports Early Positive Results For CoreoGraft Animal Feasibility Study

    IRVINE, CA / ACCESSWIRE / June 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. There have been no device failures in eight animal test subjects where CoreoGrafts have been implanted as heart bypass grafts, with one group observed at 30 days, and another group observed at 45 days post-surgery. In particular, the CoreoGrafts have showed no signs of thrombosis, aneurysmal degeneration, neointimal hyperplasia, stenosis, changes in the lumen, or other problems that are known to plague saphenous vein grafts ("SVGs") and attempts by others to create small caliber (3 mm and 4 mm) grafts.

  • ACCESSWIRE

    Primary Investigator Dr. Jorge Hernando Ulloa Reports New and Updated VenoValve Data at C3 Global Conference

    IRVINE, CA / ACCESSWIRE / June 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Sunday, June 23, 2019, Dr. Jorge Hernando Ulloa, the Primary Investigator for HJLI's first-in-human VenoValve study in Bogota, Colombia, reported new and updated data for Hancock Jaffe's first-in-human VenoValve study at the 2019 C3 Global Conference in Orlando, Florida. Dr. Ulloa's report indicated that for the first five VenoValve patients, VCSS scores, a measurement of venous disease severity graded by the clinician, have improved an average of forty-six (46%) compared to Pre-VenoValve levels.

  • ACCESSWIRE

    Hancock Jaffe Hires Brian Roselauf as Director of Research and Development

    IRVINE, CA / ACCESSWIRE / June 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced that Brian Roselauf will be joining the company as its Director of Research and Development. Mr. Roselauf will join Hancock Jaffe on June 24, 2019, and will initially focus on design verification and validation activities to prepare for the filing of the Investigational Device Exemption ("IDE") application for the U.S. pivotal trial for HJLI's VenoValve. Brian Roselauf brings 16 years of engineering product development experience and a track record of bringing concepts to commercialization within large publicly traded companies as well as startups.

  • ACCESSWIRE

    Hancock Jaffe Primary Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Report at the Venous Summit at the C3 Global Conference

    VenoValve Presentation on June 23, 2019 in Orlando, Florida IRVINE, CA / ACCESSWIRE / June 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore ...

  • What Kind Of Investor Owns Most Of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)?

    A look at the shareholders of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) can tell us which group is most powerful...